Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01321554 · BASELINE

Baseline characteristics

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) · Source last updated 2023-06-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      261
    2. group Id
      BG001
      value
      131
    3. group Id
      BG002
      value
      392
    units
    Participants
groups
  1. description
    Participants received lenvatinib 24 mg, hard capsule, orally, once daily, until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
    id
    BG000
    title
    Randomization Phase: Lenvatinib 24 mg
  2. description
    Participants received matching-placebo, hard capsule, orally, once daily until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
    id
    BG001
    title
    Randomization Phase: Placebo
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          10.57
          value
          62.1
        2. group Id
          BG001
          spread
          10.09
          value
          61.5
        3. group Id
          BG002
          spread
          10.40
          value
          61.9
    dispersion Type
    STANDARD_DEVIATION
    param Type
    GEOMETRIC_MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          136
        2. group Id
          BG001
          value
          56
        3. group Id
          BG002
          value
          192
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          125
        2. group Id
          BG001
          value
          75
        3. group Id
          BG002
          value
          200
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      261
    2. group Id
      BG001
      value
      131
    3. group Id
      BG002
      value
      392
    units
    Participants
groups
  1. description
    Participants received lenvatinib 24 mg, hard capsule, orally, once daily, until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
    id
    BG000
    title
    Randomization Phase: Lenvatinib 24 mg
  2. description
    Participants received matching-placebo, hard capsule, orally, once daily until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
    id
    BG001
    title
    Randomization Phase: Placebo
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          10.57
          value
          62.1
        2. group Id
          BG001
          spread
          10.09
          value
          61.5
        3. group Id
          BG002
          spread
          10.40
          value
          61.9
    dispersion Type
    STANDARD_DEVIATION
    param Type
    GEOMETRIC_MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          136
        2. group Id
          BG001
          value
          56
        3. group Id
          BG002
          value
          192
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          125
        2. group Id
          BG001
          value
          75
        3. group Id
          BG002
          value
          200
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice